Drugs in focus
CHRS drug pipeline →LOQTORZI
● Neutral Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available in the U.S. since October 2023.
- Next catalyst
- None dated
What to watchLOQTORZI is a commercial-stage asset generating growing but still modest revenue (Q2 2026 net sales of $13.6M, up 15% sequentially). The company reported Q3 2026 results on November 9, 2026 with a $39.3M net loss and announced a strategic prioritization plan focusing on tagmokitug/toripalimab for esophageal cancer. Watch for Q3 LOQTORZI revenue trajectory and any updates on the expedited esophageal cancer development path. The stock trades near $0.84, down from a 52-week high of $2.62, reflecting the company's cash burn and pipeline-stage focus beyond LOQTORZI.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 22 $1.43entry
- T+1 · 4mo ago 0.00%α +1.23% · $1.43
- T+5 · 4mo ago −1.40%α +1.00% · $1.41
- T+20 · 3mo ago −6.99%α −9.89% · $1.33
- T+60 · 5w ago −25.17%α −28.44% · $1.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Coherus Oncology, Inc. announced it will report its Q2 2026 results on August 5, 2026.
Key Facts
- Coherus Oncology, Inc. announced it will report its Q2 2026 results on August 5, 2026.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3331650 |
Track record
15 reports on CHRS
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.97% at T+5 after the Feb 28, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Bearish 4/10 Entry $0.5250 Now $0.5060 +3.62% settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $0.6409 Now $0.5060 −21.05% settles Feb 8
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $0.8984 Now $0.5060 −43.68% settles Jan 27
- Oct 14, 20264w ago Press Release Neutral 4/10 Entry $1.07 Now $0.5060 −52.71% settles Jan 12
- Aug 17, 202613w ago Press Release Neutral 4/10 Entry $1.34 to $0.6409 Now $0.5060 −62.24% ▼ −52.17% −50.13% vs SPY
- Jul 22, 202616w ago Press Release Neutral 1/10 Viewing Entry $1.43 to $1.07 Now $0.5060 −64.62% ▼ −25.17% −28.44% vs SPY
- Jun 15, 202622w ago 8-K Neutral 3/10 Entry $1.38 to $1.34 Now $0.5060 −63.33% ▼ −2.90% −3.90% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 4/10 Entry $1.40 to $1.37 Now $0.5060 +63.86% ▲ +2.14% +5.41% vs SPY
- May 28, 202624w ago DEFA14A Neutral 4/10 Entry $1.65 to $1.42 Now $0.5060 −69.33% ▼ −13.94% −15.67% vs SPY
- May 11, 202627w ago Press Release Mixed 6/10 Entry $1.71 to $1.27 Now $0.5060 −70.41% ▼ −26.02% −30.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers